Yesterday KEFI (KEFI), a gold and copper exploration and development company focused on the Arabian-Nubian Shield with a pipeline of projects in the Federal Democratic Republic of Ethiopia, and the Kingdom of Saudi Arabia, announced that full Project development is planned to commence by year-end 2025, at the Company’s high-grade/high-recovery Tulu Kapi Gold Project.
Comment: KEFI hit the market yesterday with news that all is in the bag and on track with Tulu Kapi within weeks. The key here is after a massive leg to the upside earlier this autumn, is how much actually commencing the project could continue to the re-rate?
Beyond the Bounce: What 2025’s Small-Cap Rebound Says About Investor Appetite
Amazing AI plc (AQSE: AAI) AAI is a global fintech group with a Digital Asset Treasury Policy that provides online consumer loans and AI finance-related services. AAI announced, following shareholder feedback, it is cancelling its spin-off plans for Amazing AI Services Ltd, a wholly owned Mauritius subsidiary, originally announced by RNS on 11 November 2025. The Board is aware of global stock exchanges tightening of requirements for companies pursuing a digital asset treasury function and is giving consideration on how to address this and will keep shareholders informed. AAI plans to have direct exposure to digital assets in line with the Aquis Cryptocurrency Policy within its Digital Asset Treasury.
Comment: There was certainly merit in the Mauritius move, as it was a solid answer to the regulatory headwinds / goalpost moving that is currently going on in the crypto space. It will be interesting to see how after abandoning the move AAI finesses the situation.
Roquefort Therapeutics plc (ROQ), the Main Market listed biotech company, is announced that further to the announcements made on 8 September, 16 October and 3 November 2025, the Company has entered into a binding exclusive license agreement with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc. regarding the worldwide exclusive rights to AO-252. AO-252 is a clinical stage, novel first-in-class, first in-human new drug alternative targeting the TACC3 protein for the treatment of multiple cancers. TACC3 is over-expressed in multiple cancers, driving chromosomal instability, metastasis, and cancer cell migration.
Comment: It is interesting, but perhaps not surprising that ROQ remains as one of the few baby biotechs whose share price remains at the low end of the range, after a strong year for the space. That said, announcements like today should be enough to move the dial, sooner rather than later.
Image Scan (IGE), a specialist supplier of X-ray screening systems for security and industrial inspection, announced that it has recently secured a double-digit unit contract with its valued Indian partner for the ThreatScan-LS1 system. This contract was awarded following a highly competitive tender process, highlighting the system’s impressive size, rugged design, and exceptional capability to efficiently handle Passive Infrared (PIR) devices activated by X-ray technology.
Comment: Shares of IGE are less than half of what they were this time last year, so the latest news and more like it could be a trigger for recovery both for this, and investor perception of the company.
Prospex Energy PLC (PXEN), the AIM quoted investment company focused on European gas and power projects, provided an update from the Selva Malvezzi production concession in Italy following the publication by Po Valley Energy Limited (ASX: PVE) of an update on activities. PVE ASX Announcement-18Nov2025. Po Valley Operations Pty Limited , a wholly owned subsidiary of PVE is the operator of the Selva Malvezzi production concession, which has a 63% working interest, while Prospex has the remaining 37% working interest.
Comment: At least in terms of the share price the market is still keeping PXEN in the doghouse. This is perhaps rather unfair, as it can be seen from the newsflow that the company is moving along, even if this is not up to scratch as far as soliciting investor interest.
Vast Resources (VAST), the AIM quoted mining company, wishes to address recurring themes in several shareholder questions submitted to the Company and its advisers, as well as those posted on public forums.
Comment: Question 3 was a cracker: Given the current financial position and the RNS of 17 November, do you anticipate the need for another placing? The Company has no current intention of conducting a placing to satisfy the 31 December 2025 debt repayment. Alas the shares are down from 0.37p in September to 0.14p now, so clearly 31 December is casting a shadow, even if the company has the cash at hand.
Disclaimer & Declaration of Interest:
The information, investment views, and recommendations in this Zaks Traders Cafe interview are provided for general information purposes only. Nothing in this interview should be construed as a promotion or solicitation to buy or sell any financial product relating to any companies under discussion or referred to or to engage in or refrain from doing so or engage in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the commentator but no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion.
